The nation of Zimbabwe has turned down a major US health deal valued at 367 million US dollars (£272m) spanning five years over the United States' insistence on sensitive information.
This move was revealed following a government memo from December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official representative has since stated that the United States was demanding access to biological samples for research and commercial gain while was unwilling to guarantee the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate process of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued talks to secure a deal acceptable to all parties so the nation's critical HIV programme can proceed.
Wider Background
This development comes after a similar case in Kenya, where a high court suspended a similar health funding agreement following legal challenges were raised about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump claimed its spending was "inefficient" and his administration was seeking government-to-government agreements to enhance transparency and responsibility.
As per statements, Sixteen nations in Africa have to date signed similar agreements, constituting over $18.3bn in committed funds.
Details of the Declined Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no corresponding guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our citizens if a future health crisis arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending systems previously established via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This framework is intended to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to ongoing discussions with our American counterparts on how future collaboration could be structured in a manner that respects the independence and dignity of each country."
Medical Community Reaction
Medical experts expressed it recognised the government's concerns, but recommended that talks must proceed considering a large portion of the country's HIV programmes depended on foreign aid.
"In cases where technical issues arise, including those relating to information security or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," the group commented.
The halted deal emphasises the continuing debate between receiving vital international aid and protecting national sovereignty in an ever more data-driven world.